Researchers believe they may have the next, better version of Ozempic in their works.
At Tufts University, scientists Increase weight loss Muscle loss and weight are also associated with common GLP-1 drugs, while reducing nausea.
The goal is as follows: “Four times the action” drug According to a press release from the study, it coincides with the effectiveness of bariatric surgery to achieve long-term weight loss of up to 30%.
Can GLP-1 weight loss drugs like Ozempic be “all medicines”?
Semaglutide drugs such as Ozempic and Wegovi mimic the natural hormone GLP‑1 (peptides‑1 such as glucagon), and tilzepatides (such as munjaro and zepbound) target both the GLP-1 receptor and the GIP (glucose-dependent insulin-induced polypeptide) receptor.
Tufts’ new drugs target a combination of four hormones: GLP-1, GIP, glucagon (response to insulin), and peptide YY, which reduces hunger, empty stomach, and reduces May. Promotes fat burning.
“We built a single experimental peptide that functions like four hormones at a time, so we didn’t push one button too hard,” lead author Tristan Dinsmore, a researcher at Tufts University, told Fox News Digital.
Carbohydrates packed with 5 proteins to help you lose weight and build muscle
“Instead, we’re fine-tuning four ‘dimmer switches’ together to manage appetite, blood sugar and energy use. ”
Because GLP ‑ 1 and Pyy can contribute to nausea at high doses, researchers rely on GIP, known to relieve nausea, to “balance things,” Dinsmore said.
“Along with supporting bloating and glucose control, GIP signaling has antiuric properties. It can even prevent nausea in preclinical models, so we prioritized it in the mix,” he continued.
“Adding pyy to the GLP ‑ 1/GIP/Glucagon trio will help you rely less on GLP ‑ 1 and glucagon, which will promote weight loss and reduce the likelihood of nausea (GLP ‑ 1/pyy). Hyperglycemia Risk (from glucagon) while maintaining profits. ”
The drug is still in the experimental/preclinical stage and has not yet been tested in human trials.
The development of this drug was featured in the Journal of the American Chemical Society.
Dr. Brett Osborne, a Florida neurosurgeon Longevity Expertsa strong supporter of GLP-1 drugs.
“Single agent GLP-1 like Ozempic for most people,” Osborn, who was not involved in the Tufts research, told Fox News Digital. “Side effects are easy to manage Experienced doctor I’ll oversee you. ”
“We don’t need any more medicines to treat the same chronic problems that are increasingly straining the world,” he added. “There are a lot of very effective GLP-1 agonists right in front of us.”
The biggest risks of GLP-1S are muscle loss and under-malnutrition, he said. To prevent this, doctors emphasize the need for proper daily protein and consistent strength training.
Treatment of “chronic” Obesity diseaseOsborne recommends micro-deadministration or intermittent administration of GLP-1 in combination with nutrition, progressive resistance training, hydration and sleep.
Risk of diabetes combined with Mediterranean diet and other lifestyle changes
“Essentially use medicines that combine it and combine it with it. Disciplined habits“He gave advice.
Sue Decotis, MD, is a medical weight loss doctor in New York City. Control your appetitepromoting metabolism and increasing fat burning is a “complex function” that balances the interactions of blood sugar and insulin.
“The additional mechanisms offered by new drugs may help some mechanisms, but not necessarily very often. Weight loss The patient was not involved in the study, Decotiis told Fox News Digital.
“Even with new mechanisms added to weight loss medications, individual patients still respond differently to the amount of fat they lose.”
She noted that patients taking GLP-1 usually do not experience muscle and bone loss.
“be careful Medical weight loss We should include body composition scales and monitoring proteins, fiber and patients with excellent hydration,” she said.
The new drug had several restrictions, the researchers admitted.
“This is a design study that introduces the next generation and perhaps the potential of tailored drugs,” Dinsmore told Fox News Digital. “Our data comes from cell-based assays, not animals or humans (still).”
“In vivo (living) studies are required to select the safest and most effective balance across the four pathways. Clinical trials. ”
Click here to sign up for our health newsletter
People who use GLP‑ 1-based drugs should stick to the guidance of their clinicians, Dinsmore advised.
“This is not a drug you can get today,” he said of the new drug. “Our work is a next-generation concept aimed at improving outcomes. Reduce nausea By spreading the work to four hormones rather than overloading one. ”
Obesity is estimated to affect more than 40% of American adults and is associated with dozens of diseases, including type 2 diabetes, heart disease, stroke and sleep apnea. Hypertension And some types of cancer.
Visit us for more health articles www.foxnews.com/health
“What drives us is the idea that we can design a single drug to treat obesity and mitigate the risk of developing a long list at the same time. Health issues A stolen society,” said Krishna Kumar, Robinson professor of chemistry at Tufts.
